8-K - Werewolf Therapeutics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Werewolf Therapeutics reported its fourth quarter and full year 2025 financial results, including a net loss of $8.4 million for Q4 2025 and $60.8 million for the full year. The company also announced it has initiated a process to explore strategic alternatives, including a potential sale, merger, or asset sale, and has engaged Piper Sandler as its exclusive financial advisor.

Key Takeaways

1The company reported a net loss of $8.4 million for Q4 2025, compared to $20.4 million in Q4 2024.

2Cash and cash equivalents were $57.1 million as of December 31, 2025, which the company believes is sufficient to fund operations into Q4 2026.

3Werewolf has initiated a process to explore strategic alternatives, including a sale of the company, business combination, merger, or sale of assets.

4Piper Sandler & Co. has been engaged as the exclusive financial advisor to assist in the strategic evaluation process.

5Research and development expenses were $6.9 million for Q4 2025, down from $15.7 million in Q4 2024.

6General and administrative expenses were $2.5 million for Q4 2025, down from $4.6 million in Q4 2024.

Current Report Details

Event Type

Financial Results

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

2.02

in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as am

Financial Results

9.01

. Financial Statements and Exhibits. Exhibit No. Description 99.1 Press release issued by the Company on March 27, 2026 104 Cover Page Interactive Data File (em

Exhibits Only

Source Document

Results of Operations

Fourth Quarter 2025

Metric	Value	Basis	Prior Period
Net Loss	$-8.38		$-20.40
Diluted EPS	$-0.20		$-0.46

Exhibits (2)

8-K

99.1

EX-99.1